Institut Pasteur

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Institut De Recherche Pour Le Developpement (ird)

Kimron Veterinary Institute

Université De La Réunion Saint Denis

Centre National De La Recherche Scientifique-cnrs

Inserm (institut National De La Sante Et De La Recherche Medicale)

Themis Bioscience Gmbh

Institut De Recherche Pour Le Developpement

Inserm

Philippe Despres

Marie-Pascale Frenkiel

Frédéric Tangy

Sylvie Paulous

Vincent Deubel

Pierre Charneau

Chantal Combredet

Adeline Catteau

Marie Flamand

Jean-Claude Manuguerra

Hugues Bedouelle

Jessica Vanhomwegen

Marianne Lucas-Hourani

Françoise Megret

Antoine Talarmin

Sophie Alcon

Erika Navarro-Sanchez

Marie-Pierre Courageot

Elodie Crublet

Philippe Souque

Gilles Gadea

Pierre-Emmanuel Ceccaldi

Jean-Louis Guenet

Mertyn Malkinson

Caroline Banet

Patrick Weber

Marie Pascale Frenkiel

Melissanne De Wispelaere

Anne-Claire Brehin

André Habel

Amadou Alpha Sall

Marie-Therese Drouet

Ali Amara

Fernando Arenzana-Seisdedos

Fasseli Coulibaly

Valerie Marechal

Samantha Brandler

Marie-Thérèse Drouet

Andre Habel

Fasséli Coulibaly

Patrick Mavingui

Michael Girardot

Elodie Brient-Litzler

Philippe Dussart

Laetitia Bremand

Wildriss Viranaicken

Jean-Louis Virelizier

Pierre-emmanuel Ceccaldi

Anne-Claire Julie Brehin

Valérie Marechal

Marie-Thérèse Institut Pasteur Drouet

Mertyn Kimron Veterinary Institute Malkinson

Caroline Kimron Veterinary Institute Banet

The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.

Lentiviral vector-based Japanese encephalitis immunogenic composition

The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.

Vaccine compositions comprising an attenuated mutant Zika virus

The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored.

Genomic sequences encoding for an attenuated mutant Zika virus

The present invention provides an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres). The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.

Multiplex immuno screening assay

The invention relates to building a chimeric polypeptide used for preventing or treating a Flaviviridae infection. The use of the inventive chimeric polypeptide for producing recombinant viral vectors such as a measles living viral vector is also disclosed.

Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection

The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres), said support being previously coated with an AGT substrate. This coupling is mediated by the irreversible reaction of the AGT enzyme on its substrate. The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures. The methods of the invention possess the ability to multiplex, minimize the amount of biological sample, and have enhanced sensitivity and specificity toward target antibodies as compared with classical ELISA or Radio-Immunoprecipitation assays.

The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.1.63), a mutant or a catalytic domain thereof, and c) a recombinant protein. Said MGMT enzyme is preferably the so-called SNAP protein.

MGMT-based method for obtaining high yeilds of recombinant protein expression

The invention relates to recombinant Measles virus expressing Chikungunya virus polypeptides, and concerns in particular virus like particles (VLP) that contain envelope and capsid proteins of a Chikungunya virus at their surface. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Chikungunya virus.

Recombinant measles virus expressing chikungunya virus polypeptides and their applications

Chimeric poly peptides and the therapeutic use thereof against a Flaviviridae infection

MGMT-based method for obtaining high yields of recombinant protein expression

The present invention concerns wild-strains of Chikungunya virus isolated from patients exhibiting severe forms of infection and stemming from a human arbovirosis epidemy. The present invention also concerns polypeptide sequences and fragment thereof derived from their genome, the polynucleotide encoding same and their use as diagnostic products, as vaccine and/or as immunogenic compositions.

Isolated and purified strains of Chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof

Growing community of inventors

La Garenne Colombes, France

Philippe Despres